Related Experiment Video

Updated: Jul 30, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Current therapy and development of therapeutic agents for lung cancer

Zilai Wang1, Jiyeon Kim2, Pin Zhang1

  • 1Chicago BioSolutions, Inc., 2242 W Harrison Street, Chicago, IL, 60612, USA.

Cell Insight
|May 16, 2023
PubMed

Insights

Lung cancer treatment has advanced with targeted therapies for non-small-cell lung carcinoma (NSCLC) and immune checkpoint inhibitors. Future research focuses on small-cell lung carcinoma (SCLC), brain metastasis, and overcoming resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer remains a leading global cause of cancer death despite decades of progress.
  • Significant advancements have been made in targeted therapy for non-small-cell lung carcinoma (NSCLC).
  • Limited progress has been achieved in developing targeted drugs for small-cell lung carcinoma (SCLC).

Purpose of the Study:

  • To review the genetic and molecular characteristics of lung cancer subtypes.
  • To summarize current and developing treatment options, including targeted therapies and immunotherapies.
  • To explore novel therapeutic targets and preclinical agents for lung cancer.

Main Methods:

  • Literature review of genetic and molecular characterization of lung cancer.
  • Analysis of current treatment options and drugs in clinical development.
  • Elaboration on receptor tyrosine kinase (RTK) targets and preclinical agents.

Main Results:

  • Targeted therapies, including multiple generations of small molecule inhibitors, have shown remarkable success in NSCLC.
  • Immune checkpoint inhibitors targeting PD-1/PD-L1 represent a major advancement in lung cancer treatment.
  • Development of targeted drugs for SCLC remains significantly less advanced compared to NSCLC.

Conclusions:

  • Future lung cancer treatment strategies should focus on addressing brain metastasis and tumor heterogeneity.
  • Combining molecular testing with tailored strategies is crucial for overcoming resistance mechanisms.
  • Continued research into novel targets and agents is essential for improving patient outcomes in both NSCLC and SCLC.
Keywords:
BiomarkersImmunotherapyLung cancerNon-small cell lung carcinomaReceptor tyrosine kinase inhibitorsReceptor tyrosine kinasesSmall cell lung carcinomaSmall molecule drugsTargeted therapies

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
512
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
587